investor harm

Class action lawsuit alleges Nektar Therapeutics misled investors about REZOLVE-AA trial enrollment standards, claiming executives made false statements about trial integrity.

Class action lawsuit filed against $SMCI for allegedly concealing significant Chinese sales violating U.S. export controls and hiding compliance weaknesses.

Class action lawsuit filed against $DRVN alleging securities fraud, claiming false financial statements and weak internal controls from May 2023 through February 2026.

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 clinical trials. Investors can join by April 6, 2026.

Class action filed against $IT alleging materially false statements on contract value growth and consulting segment performance during February 2025-2026 period.

Apollo Global Management faces class action lawsuit alleging executives misled investors about Jeffrey Epstein business dealings. Investors may be eligible to join if they purchased securities between May 2021 and February 2026.

Class action lawsuit filed against Corcept Therapeutics alleging false statements about relacorilant drug's clinical strength and FDA approval prospects.

Class action filed against NASDAQ-listed CIGL for alleged stock promotion fraud involving fake social media accounts, impersonated advisors, and insider share dumping through offshore accounts.

Class action filed against Aldeyra Therapeutics alleging false reproxalap trial data claims; investors from Nov 2023-Mar 2026 may be eligible.

Class action lawsuit filed against $LAKE alleging executives made false statements about Pacific Helmets and Jolly business performance while concealing operational challenges.

Class action lawsuit filed against $BSX alleging materially false statements regarding U.S. electrophysiology segment growth projections and undisclosed adverse trends.

Class action lawsuit filed against Coty Inc. alleging executives made false statements about growth prospects during November 2025-February 2026 period.

Class action lawsuit filed against AMC Entertainment over APE dividend exclusion, alleging securities fraud and material misrepresentations regarding investor protections.

Class action lawsuit filed against $PLUG alleging false statements about DOE funding and hydrogen facilities between January and November 2025. Investors can seek lead plaintiff status by April 3, 2026.

Class action filed against $UGXY alleging misleading statements about Phase III Orbit study for rare bone disease treatment. Investors may recover losses from August 2023 forward.

Class action filed against $PINS for alleged false statements on advertising revenue, tariff management, and failure to disclose restructuring plans.

Class action lawsuit filed against Vital Farms for allegedly concealing ERP system delays that caused the company to miss 2025 earnings guidance, affecting investors from May 2025 through February 2026.

Class action filed against $INO alleging executives made false statements about CELLECTRA device manufacturing and INO-3107 regulatory timeline between October 2023 and December 2025.

Class action lawsuit filed against $PMI alleging securities fraud, insider share dumping via offshore accounts, and omitted risk disclosures from September-October 2025.

Class action filed against $CHOW alleging securities fraud, false statements, and undisclosed market-manipulation scheme involving social media misinformation and fraudulent trading.